Docetaxel is active in patients with unresectable metastatic or locally advanced pancreatic cancer

By  

Inpharma, Vol. 1, Iss. 1248, 2000-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Comparative Pharmacokinetics and Metabolic Pathway of Gemcitabine During Intravenous and Intra-arterial Delivery in Unresectable Pancreatic Cancer Patients

By Shamseddine Ali I.  

Clinical Pharmacokinetics, Vol. 44, Iss. 9, 2005-01 ,pp. : 957-967

Adis International

Access to resources Recommend Favorite

Intra-arterial gemcitabine for unresectable pancreatic cancer

By  

Inpharma, Vol. 1, Iss. 1504, 2005-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer

By Faris Jason  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1614-1620

Springer Publishing Company

Access to resources Recommend Favorite

Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer

By Spano Jean-Philippe  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1531-1539

Springer Publishing Company

Access to resources Recommend Favorite